logo
  

Cypress Semiconductor Increases Offer For ISSI To $22.25/shr - Quick Facts

Cypress Semiconductor Corp. (CY) said that it increased its offer to acquire Integrated Silicon Solution Inc. (ISSI) to $22.25 per share, while maintaining its previously outlined ticking fee of $0.10 per share per quarter beginning October 1, 2015.

Additionally, Cypress said it will put into escrow through its lawyers today a merger agreement pre-negotiated with ISSI and signed by its Chief Executive Officer to further demonstrate its sincerity and strong commitment to closing this transaction.

Cypress noted that its proposal is clearly superior to an Uphill proposal at the same price per share, given its inclusion of a ticking fee and its mitigation of regulatory risk.

Meanwhile, the Uphill Proposal is still plagued with significant governmental (CFIUS) timing and closing risks along with mandated Taiwan divestitures, Cypress said.

Last week, Integrated Silicon Solution announced it entered into a further amendment to the merger agreement with Uphill Investment Co. As a result, the merger consideration was further increased to $22.00 per share in cash, from the $21.00 per share.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT